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Lipodystrophy and metabolic alterations are major complications of antiretroviral therapy in HIV-infected patients. In vitro
studies using cultured murine and human adipocytes revealed that some protease inhibitors (PIs) and nucleoside reverse
transcriptaseinhibitors(NRTIs)wereimplicatedtoadiﬀerentextentinadiposecelldysfunctionandthatachronicincubationwith
some PIs decreased mRNA and protein expression of PPARγ. Defective lamin A maturation linked to PI inhibitory activity could
impede the nuclear translocation of SREBP1c, therefore, reducing PPARγ expression. Adipose cell function was partially restored
by the PPARγ agonists, thiazolidinediones. Adverse eﬀects of PIs and NRTIs have also been reported in macrophages, a cell type
that coexists with, and modulates, adipocyte function in fat tissue. In HIV-infected patients under ART, a decreased expression
of PPARγ and of PPARγ-related genes was observed in adipose tissue, these anomalies being more severe in patients with ART-
inducedlipoatrophy.AlteredPPARγ expressionwasreversedinpatientsstoppingPIs.TreatmentofpatientswithagonistsofPPARγ
could improve, at least partially, the subcutaneous lipoatrophy. These data indicate that decreased PPARγ expression and PPARγ-
related function, resulting from ART-induced adipose tissue toxicity, play a central role in HIV-related lipoatrophy and metabolic
consequences.
Copyright © 2009 Martine Caron et al.ThisisanopenaccessarticledistributedundertheCreativeCommonsAttributionLicense,
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
1.Introduction
HIV-associated lipodystrophy (LD) is a disorder character-
ized by a selective damage of the adipose tissue resulting
in part from antiretroviral drugs [1, 2]. The LD syndrome
includes progressive subcutaneous fat loss and/or central fat
accumulation along with dyslipidemia, glucose alterations,
and insulin resistance, altogether generating cardiovascular
dysfunctions [3, 4]. Recent studies have hypothesized that
HIV itself could play a role in the LD phenotype (see
Giralt et al. [5]). However, the risk of developing fat
tissue redistribution has been related in priority to the
antiretroviral treatment (ART) and mainly to the use of two
classes of drugs, protease inhibitors (PIs) and nucleoside
reverse transcriptase inhibitors (NRTIs) [6–8]. Lipoatrophy
in the face and extremities has been linked repeatedly to
the use of stavudine (and to a lesser extend zidovudine)
among NRTIs [7, 9, 10] and increases with long-term
exposure [11]. PIs have been mainly associated with central
fat accumulation along with insulin resistance. However,
nelﬁnavir or indinavir can independently decrease limb fat
level in patients cotreated with NRTIs [7, 12]. Peripheral fat
loss and central fat accumulation can occur simultaneously,
though lipoatrophy may emerge as the more dominant
feature on prolonged treatments [12, 13]. Recently, a role for
the nonnucleoside analog efavirenz in lipoatrophy has been
reported but needs to be conﬁrmed [14].
Thepathogenesisofadiposecelldysfunctionincludesthe
mitochondrial toxicity of NRTIs [15–19] and the adverse
eﬀects of PIs and NRTIs on the adipocyte diﬀerentiation
status [17, 20–26], insulin sensitivity [27, 28], survival [17,
18, 23, 29], ability to secrete a variety of adipokines [30–33],2 PPAR Research
and longevity [19, 34]. The oxidative stress induced by both
P I sa n dN R T I sa tt h ef a tc e l ll e v e l[ 19, 28, 33–35]p r o b a b l y
plays a major role in the setup of lipodystrophy.
Severe adipose tissue alterations have been reported
in HIV-infected patients with ART-related lipodystrophy.
Lipoatrophic adipose tissue biopsies present major histo-
logical alterations with decreased and heterogeneous size
of adipocytes, increased ﬁbrosis, altered mitochondria, and
macrophage inﬁltration [1, 2, 36–38], consistent with a pro-
foundremodelingofsubcutaneousfattissue.Thepresenceof
isolated fat droplets, macrophages, and apoptotic cells in the
enlargedvascularstromaarguesforaprogressive destruction
of subcutaneous adipocytes [1, 2, 29, 37, 39, 40].
PPARγ is expressed in priority in adipocytes. It is also
expressedin diﬀerent othercelltypesincluding macrophages
and regulates genes associated with growth, diﬀerentiation,
insulinsensitivity,inﬂammation,andimmunity[41–46](see
[5]). PPARγ plays an essential role in the development and
normal function of white adipocytes, where it mediates
part of the regulatory eﬀect of dietary fatty acids on gene
expression [43, 47], regulates the diﬀerentiation program
[48] and insulin sensitivity [45]. PPARγ also controls the
production and secretion of adipokines such as leptin and
adiponectin,whichareimportantmediatorsofinsulinaction
in peripheral tissues [42]. In brown adipocytes, PPARγ also
controls the adipogenic program and the switch from white
to brown adipocytes [49]. In macrophages, PPARγ controls
alternative activation and improves insulin resistance [50].
It plays an important role in macrophage inﬂammation
and cholesterol homeostasis and inhibits the production of
proinﬂammatory cytokines through inhibition of the NFκB
and AP-1 pathways [48, 51–54].
Loss-of-function or dominant-negative mutations in the
P P A R Gg e n ei nh u m a n s( s e e[ 5]), and genetically-induced
PPARγ deﬁciency in mice [55, 56] are responsible for
lipodystrophic syndromes with insulin resistance, showing
the primarily involvement of PPARγ defects in adipose
tissue development and metabolic roles. Alternatively, other
causesofadipocytediﬀerentiationdefectsleadtoasecondary
decreased PPARγ expression and/or function, that further
contribute to adipose tissue dysfunction, as shown in vivo
in murine models [57]o ri nv i t r o[ 58–60].
In that setting, the implication of PPARγ in the ART
eﬀect has been demonstrated both in vitro, in cultured
adipocytes and macrophages, and ex vivo, in adipose tissue
samples from patients, and has been conﬁrmed by the
beneﬁcial eﬀects, at least partial, of the PPARγ agonists, thia-
zolidinediones. PPARγ defects, although probably secondary
to the multiple deleterious consequences of ART on adipose
tissue, play a central role in ART-related lipodystrophy and
metabolic alterations.
2. Effects of ART on PPARγ Expressionand
SignalinginCulturedAdipocytes
PPARγ contributes to the setup of the diﬀerentiation pro-
gram and to insulin sensitivity. PIs and NRTIs, the two
major classes of antiretrovirals associated with lipodystrophy
in HIV-infected patients, may interfere at several steps of
PPARγ signaling in adipose cells, such as diﬀerentiation,
insulin action, oxidative stress, inﬂammation, and mito-
chondrial function.
A number of studies have clearly shown that the ﬁrst
generation PIs, indinavir, nelﬁnavir, and ritonavir, used
at concentrations comparable to their Cmax in patients’
serum or at suprapharmacological concentrations, impaired
adipocyte diﬀerentiation [20, 21, 23, 25, 26, 32, 61–67]. They
were also shown to induce insulin resistance [21, 23, 27,
33, 62, 67–70] in murine and human cultured adipocytes.
This was associated with a reduced protein and mRNA
expression of PPARγ in both murine [20, 21, 25, 26, 64]a n d
human adipocytes [24, 66, 71, 72]. Interestingly, decreased
PPARγ expression was also observed in mature adipocytes
chronically incubated with PIs, consistent with PI-induced
adipose cell dediﬀerentiation.
Most PIs (nelﬁnavir, indinavir, saquinavir, ritonavir, and
amprenavir) were shown to acutely inhibit insulin activation
of glucose uptake in cultured adipocytes, via a direct
inhibition of the glucose transporter Glut4 [73]. Indinavir
and nelﬁnavir also altered the activation of proximal steps in
insulin signaling as revealed by decreased phosphorylation
of extracellular-regulated kinase (ERK) 1/2 and Akt/protein
kinase B. Accordingly, distal events in insulin signaling path-
ways, glucose transport, and lipogenesis were also aﬀected
[21, 30, 74]. Regarding PPARγ, cell imaging studies revealed
that indinavir and nelﬁnavir but not amprenavir severely
decreased nuclear expression of PPARγ [21], indicating for
the ﬁrst time that the transcriptional activity of PPARγ may
bedefectiveinPI-treatedcells.Thebeneﬁcialeﬀectofrosigli-
tazone [21, 23, 32] conﬁrmed the implication of PPARγ in
PI action, and indicated that PIs act upstream of PPARγ in
its signaling cascade to alter adipocyte diﬀerentiation and
insulin sensitivity. Recent data of our laboratory further
support the implication of PPARγ in PI action by showing
that two angiotensin II-receptor blockers (telmisartan and
irbesartan), that display partial PPARγ agonist activity [75],
prevented the PI eﬀects on lipid accumulation and insulin
response in murine and human adipocytes (Boccara F. et al.,
unpublished results).
The eﬀect of ritonavir on insulin signaling has been
particularly studied since this commonly prescribed PI is
associated with dyslipidemia and metabolic disorders in
HIV-infected patients [67, 76, 77]. Ritonavir induced insulin
resistance in cultured adipocytes [24, 32, 64]. Another
study reported that ritonavir reduced diﬀerentiation and
insulin sensitivity in human preadipocytes and adipocytes
but surprisingly without decreasing PPARγ2 gene expression
[68]. However, the protein expression and the activation of
PPARγ have not been evaluated in this study.
The mechanism whereby PIs alter adipose cell diﬀer-
entiation and insulin sensitivity is obviously complex and
multifactorial. Impaired SREBP-1 nuclear penetration [21,
22]mayinhibittheactivationofPPARγorrelatedadipogenic
transcription factors thus leading to defective adipogenesis
and insulin resistance. When going further into the mech-
anism of PI action, we and others demonstrated that some
PIs prevented the maturation of lamin A/C [22, 34, 78],PPAR Research 3
a nuclear membrane protein essential for normal nuclear
membrane folding and for nuclear penetration of SREBP-1
[59, 79, 80]. Defective SREBP-1c signaling may explain the
decreased diﬀerentiation and insulin resistance of PI-treated
cells and the ability of PPARγ agonists to overcome the PI
eﬀects on fat cell diﬀerentiation and insulin response [21].
NRTI therapy is also associated with fat tissue disease
in HIV-infected patients. In murine adipose cell lines and
primary cultured human adipocytes, stavudine and zidovu-
dine, but not other NRTIs (tenofovir, abacavir, didanosine,
and lamivudine), alter lipid storage [23, 31, 33, 81]. They
also decrease the expression and secretion of adiponectin
in cultured human and murine adipocytes [23, 32, 33,
82] and induce oxidative stress, suggesting that they could
secondarily participate to the insulin resistance setup [33].
The negative eﬀect of NRTIs on PPARγ expression and
signaling has been reported only in a few studies. Stavudine
or zidovudine have a modest, or no eﬀect, on adipose cell
diﬀerentiation assessed by the gene expression proﬁle of
diﬀerentiating adipocytes [25] and by protein and mRNA
expression of adipogenic transcription factors, among them
PPARγ [20,25,31,32,82].Alteredadipocytelipidphenotype
and insulin sensitivity resulting from NRTI treatment are
suspected to result from their mitochondrial toxicity [15–
18]. We recently reported that stavudine or zidovudine, but
not other NRTIs, triggers mitochondrial oxidative stress and
premature senescence in cultured ﬁbroblasts and adipocytes
[19]. Stavudine also altered in human preadipocytes [72]
the expression of the PPARγ coreceptor 1-alpha (PGC1-
α) a transcriptional coactivator upregulated by thiazo-
lidinediones which controls mitochondrial function and
biogenesis, and metabolic pathways and integrates insulin
signaling and mitochondrial function [83, 84]. Stavudine
increased its expression together with mitochondria number
[72].Thus,converselytoPIs,invitro,thymidineanalogshave
no or mild detrimental eﬀect on PPARγ function.
The non-NRTI class of antiretrovirals has not yet, as
a class, been associated with long-term toxicity [7]e v e n
if efavirenz was shown in one study to be associated with
lipoatrophy [14]. Very few studies report experimental in
vitro ﬁndings on the eﬀects of the non-NRTIs efavirenz or
nevirapine on white adipose cell functions. Efavirenz but
not nevirapine induced a delayed and moderate reduction
in lipid accumulation in both murine and human cultured
adipocytes, and decreased SREBP-1c and PPARγ expression
[85].
3. Effect of ART on PPARγ Expressionand
Function in AnimalModels
Ritonavir was shown to increase lipogenesis [86]a n dt o
induce insulin resistance in animal models [87]. In mouse
fat tissue, it partially inhibits the function of PPARγ as
shown by the decreased induction of PPARγ target genes
by rosiglitazone [88]. Lopinavir-ritonavir but not atazanavir
decreased by 25% the weight of peripheral inguinal fat in
mice treated for 8 weeks, while the profound epididymal
adipose tissue depot was not aﬀected. The expressions of
SREBP-1c and of its target gene fatty acid synthase were
increased in the peripheral inguinal fat while that of PPARγ
tendedtobedecreasedinthetwodepotsandthatofitstarget
gene adiponectin was not modiﬁed [89]. Even if not entirely
conclusive, these data are in favor of an altered expression
and/or function of PPARγ induced by some PIs in murine
models.
4. Effect of ART on PPARγ Expressionand
Function in Patients’ Adipose Tissue
Studies performed on human adipose tissue samples studied
ex vivo concerned, at ﬁrst, healthy controls treated with ART.
Mallon et al. [90] reported that a 2-week treatment with
stavudine/lamivudine or zidovudine/lamivudine resulted in
an increased expression of PGC1α and PPARα and a
decreased expression of PPARγ without any modiﬁcation
in the expression of SREBP1. Altered expression of PGC1α
was correlated with upregulation of nuclear genes involved
in transcription regulation of mtRNA and oxidation of fatty
acids suggesting a central role for PGC1 in nuclear response
to mitochondrial dysfunction.
Several studies evaluated the expression of PGC1α and
PPARγ in adipose tissue from long-term ART treated HIV-
infected patients with lipodystrophy. A decreased expression
of the two factors was reported in abdominal fat from
lipodystrophic patients as compared to controls [36, 37]a n d
to non-lipodystrophic patients [91]. A decreased expression
of PPARδ was also found in this latter study. Accordingly,
a decreased expression of the transcription factor SREBP-
1 was also reported [36, 91, 92]. PPARγ adipose tissue
expression was found decreased in HIV-infected patients
as compared to noninfected controls by Giralt et al. [5]
but the major decrease was observed in na¨ ıve versus ART-
treated patients, without diﬀerences between lipodystrophic
and nonlipodystrophic patients, arguing for a major role
for the virus itself. The expression of PGC1α was increased.
The group of D. Nolan and S. Mallal observed that the
PPARγ2 mRNA level was similar in fat from treatment-na¨ ıve
patients and in patients under PI or zidovudine but lower
in patients under stavudine. However, noninfected controls
were not evaluated in that study [93]. Interestingly, adipose
tissue dysfunction appears more severe in peripheral than
in abdominal subcutaneous adipose tissue, as shown by the
decreased expression of PPARγ, C/EBPα, and adiponectin in
adipose tissue from thigh versus abdomen [94]. Therefore,
a strong alteration in PPARγ expression was found in
most studies using HIV-infected patients’ subcutaneous fat
samples.
To examine the reversibility of adipose tissue alterations
in HIV-infected patients, adipose tissue biopsies were stud-
ied before and after a 6-month interruption of ART in
the Lipostop study. Adipose tissue inﬂammation improved
markedly, with fewer inﬁltrating macrophages and fewer
TNFα- and IL6-expressing cells.mRNA expression of PPARγ
and of markers of mitochondrial function and biogenesis
(cytochrome oxidase subunit 2 and PGC1α)i m p r o v e da f t e r
PI withdrawal. In patients who stopped taking stavudine4 PPAR Research
or zidovudine, adipose tissue inﬂammation, mitochondrial
status, and SREBP-1 expression were improved [95]. Since
PGC1α is playing a leading role in mitochondria function
[84],thisindicatesthatalteredPGC1αandPPARγ expression
induced by some ART may be involved in mitochondria
dysfunction observed in patients’ fat [90, 95].
Decreased PPARγ expression was also strongly correlated
with increased expression of inﬂammatory cytokines such as
IL-6 and TNF-α and decreased expression and circulatory
levels of adiponectin which is involved in liver and muscle
insulin sensitivity [1, 36, 37, 91, 96]. These data conﬁrm
that altered PPARγ function in adipose tissue plays a role
in overall insulin resistance associated with lipodystrophy,
as reported in genetically-determined PPARγ dysfunctions
[45]. In accordance, the study from Sutinen et al. [97]
reported the eﬀects on adipose tissue of a 24-week treat-
ment with the PPARγ agonist rosiglitazone compared with
placebo in HIV-infected patients with lipodystrophy. The
expression of adiponectin, PPARγ, and PGC1α signiﬁcantly
increased while that of IL-6 decreased. Expression of other
genes involved in lipogenesis, fatty acid metabolism, or
glucose transport, such as PPARδ, and SREBP-1, remained
unchanged. Rosiglitazone also signiﬁcantly induced an
increase in serum adiponectin concentration, which was
inversely correlated with the changes in fasting serum insulin
concentration and liver fat content. Such data have led
to conduct clinical trials using thiazolidinediones to try
to reverse peripheral fat loss. Even if the results obtained
with rosiglitazone were disappointing (see [97]), possibly
due to the ongoing presence of stavudine in the ART
regimen, recent data obtained with pioglitazone are more
promising and reveal, in patients not treated with stavudine,
an improvement of peripheral fat [98] further supporting a
role for PPARγ dysfunction in lipoatrophy.
5. PPARγ Expressionand Fat Hypertrophy in
HIV-InfectedPatients
The lipodystrophic phenotype observed in HIV-infected
patientsassociates,todiﬀerentextent,peripherallipoatrophy
and fat hypertrophy in diﬀerent fat depots. In particular, a
buﬀalo hump has been observed in a number of patients.
The group of F. Villaroya showed that buﬀalo humps from
HIV-infected patients displayed a brown adipose tissue
phenotype with both speciﬁc uncoupling protein 1 (UCP1)
expression and mitochondrial dysfunctions [99]. However,
there were no signiﬁcant changes in the expression of other
UCP genes or of that of markers of adipogenesis including
PPARγ,P G C 1 α, and adiponectin relative to controls. A more
extensiveanalysisindicatedthatbuﬀalohumptissuedoesnot
express a complete brown adipocyte phenotype but rather
a distorted brown-versus-white phenotype associated with
enhanced proliferation [2]. In addition, buﬀalo humps failed
to show increased expression of TNFα or the macrophage
marker CD68 indicating the absence of a local inﬂammatory
status. Since adipose tissue inﬂammation and the presence of
proinﬂammatory cytokines has been presumed to play a role
in subcutaneous fat lipoatrophy in HIV-infected patients,
this absence of inﬂammation could explain, at least in part,
the absence of fat loss observed in that depot.
The eﬀect of antiretrovirals on brown adipocytes has
been evaluated in two studies. In primary culture of diﬀer-
entiated murine brown adipocytes, neither the cell diﬀeren-
tiation nor the level of PPARγ was modiﬁed by the treatment
with a series of NRTI including stavudine and zidovudine.
By contrast, regarding the NNRTI, nevirapine increased
and efavirenz decreased brown adipocyte diﬀerentiation and
PPARγ expression. PGC1α expression was not modiﬁed by
the drugs except for its increase in response to stavudine
and nevirapine [100]. In the T37i brown adipocyte cell-line,
indinavir, stavudine, and zidovudine alone or in association
impaired PPARγ2 and UCP1 expression together with a
strong inhibition of cell diﬀerentiation and mitochondrial
functions, although the 3T3-F442A white adipocyte cell
line, studied under similar conditions, was less severely
aﬀected [26]. Therefore, brown fat can also be a target of
antiretrovirals. Since the presence of brown adipose tissue
in normal humans has been recently reassessed [101], it
wouldbeimportanttofurtherevaluateitsalterationsinHIV-
infected patients under ART.
Increased visceral fat is also a characteristic feature of
HIV-related lipodystrophy. However, samples from patients
are diﬃcult to obtain and no study, up to now, has reported
speciﬁc data obtained with HIV-infected patients’ visceral
fat. A few studies compared the eﬀect of antiretrovirals on
adipocytes issued from subcutaneous and visceral fat from
noninfected subjects but the expression of PPARγ or PGC1
was not evaluated.
6. PPARγ andMacrophages
PPARγ plays an important role in macrophage function and
phenotype and exerts an overall anti-inﬂammatory function
(see [5]). Recent data have shown that adipose tissue from
obese individuals presents macrophage inﬁltration as well
as increased number of “M1” or “classically activated”
macrophages. Importantly, the agonists of PPARγ have been
shown to alter macrophage phenotype to “M2” or an
“alternatively activated” anti-inﬂammatory phenotype and
may induce macrophage speciﬁc cell death [102]. PIs could
alter PPARγ in macrophages by increasing PPARγ mRNA
expression resulting in foam cell formation [103]. In the
Lipostop study [95], we observed that stopping ART resulted
in an improvement of adipose tissue function associated
with a decreased number of M1 but not M2 macrophages
together with an increased expression of PPARγ.T h i sc a n
result from modiﬁed PPARγ expression both in adipocytes
and macrophages.
7. Conclusion
In vitro and in vivo data strongly suggest that altered
PPARγ function plays a role in HIV-related lipodystrophy
as a result of a multifactorial toxicity of ART on adipose
tissue. In vitro studies investigating the eﬀect of individual
antiretrovirals have clearly revealed that some PIs inhibit
PPARγ functions, probably at the earlier step of SREBP1cPPAR Research 5
activation. Ex vivo studies of adipose tissue, both in healthy
volunteers and in HIV-infected patients, conﬁrmed these
data but also point to a possible toxicity of NRTI, principally
stavudine and to a lesser extent, zidovudine. Since PPARγ is
playing a central role in adipose tissue diﬀerentiation and
function, decreased PPARγ expression could be expected
to be involved in the pathophysiology of lipodystrophy.
Importantly, both adipocytes and macrophages present in
patients’ adipose tissue can be aﬀected at the PPARγ level.
Adipose tissue dysfunction could induce insulin resistance
and deregulate adipokine secretion with increased release
of proinﬂammatory cytokines and decreased adiponectin,
alterations which will impact on the liver and muscles.
Most studies in that setting evaluated the expression and
function of PPARγ and only scarce data are available for
PPARα and PPARδ.
Using thiazolidinediones to reverse fat lipoatrophy was a
logical proposition. However, trials using rosiglitazone were
disappointing, in part due to the absence of discontinuation
of stavudine. Pioglitazone was more promising and resulted
in some recovery of limb fat further arguing for a role for
PPARγ in initial fat alteration.
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